Navigation Links
Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Date:9/21/2007

vival (OS) will be evaluated as secondary endpoints in the study.

AstraZeneca is currently investigating vandetanib through an extensive NSCLC clinical trial program.

About Study 6

This randomized, double-blind, placebo -controlled Phase II trial evaluated the activity of vandetanib 100mg and 300mg in combination with standard docetaxel therapy (75 mg/m2 via intravenous infusion every 21 days) in 127 patients with advanced (stage IIIb/IV) NSCLC, including squamous cell carcinoma, after failure of first-line platinum-based chemotherapy.

Patients were randomized to vandetanib 100 mg + docetaxel (n=42), vandetanib 300 mg + docetaxel (n=44), or Docetaxel alone (n=41). The prolonged median progression-free survival (PFS) was 18.7 weeks (HR=0.64, 95% CI 0.38 - 1.05; p=0.074) and 17 weeks (HR=0.83, 95% CI 0.50-1.38; p=0.461) respectively, compared to 12 weeks with docetaxel alone.(2)

In this study, treatment with vandetanib was associated with asymptomatic QT prolongation (extended time interval between heartbeats). Other common adverse events (AEs) included diarrhea and rash. All AEs responded to standard management or dose interruption or reduction.

Due to the small number of patients involved, and the fact that survival data was potentially confounded by subsequent therapies, further assessment of survival outcomes will be investigated in Phase III trials. There was no significant effect of vandetanib on overall survival.

About Lung cancer

Over 1.35 million new cases of lung cancer are diagnosed every year and nearly 1.2 million people die as a result of this devastating disease - more than breast, colon and prostate cancer combined.(3)

If lung cancer is detected at early stages, before it has spread to other organs or lymph nodes, around half of patients can survive for five years or more. However, few lung cancers are found at this early stage and it is normally diagnosed at the advanced stage, when five-year survi
'/>"/>

SOURCE AstraZeneca
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
2. Newly Published Data from Large Study Support Cardiovascular Safety of Avandia (Rosiglitazone Maleate)
3. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
4. Adding Thalidomide to Standard Therapy Improves Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75
5. Newly Published Study Reveals Femara Improves Chances for Harder to Treat Early Breast Cancer Relapse in Postmenopausal Women
6. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
7. ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03) Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival Advantage for Patients with Multiple Myeloma
8. MRI Detects Cancers in the Opposite Breast of Women Newly Diagnosed with Breast Cancer
9. Nymox Announces Positive Results from Newly Completed Long-term Study of NX-1207 for Benign Prostatic Hyperplasia
10. Newly Released Canadian Data Links Vaccines with Pervasive Developmental Disorder
11. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 The Cadence Fitness & Health Center ... the Medical Fitness Association, a non-profit organization assisting medically ... potential. The Cadence Fitness & Health Center is the ... second in the Chicagoland area. "The certification ...
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: Global ... Systems -- Focus on End Users ... OBJECTIVES A drug delivery system ...
(Date:1/14/2014)... 2014  Luminex Corporation (Nasdaq: LMNX ) today announced ... of 2013 on Monday, February 3, 2014. A press release ... of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... operating highlights and financial results for the fourth quarter and ...
Breaking Medicine Technology:Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
(Date:4/17/2014)... (17 April 2014) Population Council scientists and their partners ... stable, and can prevent the transmission of multiple sexually ... in animals: HIV, herpes simplex virus 2 (HSV-2), and ... first data that the gel is effective against multiple ... in the vagina against all three viruses of at ...
(Date:4/17/2014)... and alleviates muscle soreness after exercise, according to ... Illinois at Chicago. , The study, reported online ... of Physical Medicine and Rehabilitation , also showed ... had not exercised, suggesting that massage has benefits ... activity. , Improved circulation and relief of muscle ...
(Date:4/17/2014)... cent of Canadians surveyed said they would participate in ... number of genetic conditions, only 80 per cent said ... would sequence their newborns, genomes.,Most newborns in North America ... or two of life in which a tiny amount ... for about five to 54 conditions, depending on the ...
(Date:4/17/2014)... status as the leading weapon against the deadly disease ... new research indicating it simply needs to be administered ... the cheap anti-malarial drug chloroquine in treating and preventing ... than half a million people each year around the ... resistance to chloroquine, but research carried out at the ...
(Date:4/16/2014)... The Translational Genomics Research Institute (TGen) recently honored two ... their support of TGen,s research into brain, colon and ... Scottsdale. , Catherine Ivy, Founder and President of The ... McCain Leadership Award, named for U.S. Sen. John McCain ...
Breaking Medicine News(10 mins):Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2Health News:Massage therapy improves circulation, eases muscle soreness 2Health News:Researcher looks at public perceptions around newborn testing 2Health News:Researcher looks at public perceptions around newborn testing 3Health News:Scientists find new way to fight malaria drug resistance 2Health News:TGen honors Catherine Ivy and Craig Jackson with Leadership; Collaborative Spirit awards 2
... blocks muscle growth, has shown promising results as a ... studies, where its inhibition led to increased muscle mass ... a myostatin inhibitor in patients, assessed its safety in ... well-tolerated. The study was published today in Annals of ...
... in Boone County to house world class research, center in country,s ... of personalized medicine into mainstream ... ... MHS ), joined by Indiana Gov. Mitch Daniels, broke,ground today on its ...
... Holdings Corp.,(Nasdaq: HMSY ) today announced that it ... which will be held March 26-27, 2008 at the ... of HMS Holdings Corp., will,present on Wednesday, March 26th ... HMSY ) is a national leader in cost,containment ...
... hospitals will aggravate existing problems, ... ... state legislators to reject a proposal to,eliminate the state,s planning process for ... huge cuts in,funding to care for the elderly and poor, and already ...
... recurrent or new tumors by more than half, study found ... good news for the 60 percent of women with breast ... inhibitor (AI) drug letrozole (Femara) can cut risk of a ... even when women initiated the drug one to seven years ...
... &,Johnson will participate in the Eleventh Annual Lehman ... the Loews Miami Beach Hotel,in Miami, Florida. Dominic ... represent the Company in a session scheduled at,11:15 ... available to investors and other interested parties,by accessing ...
Cached Medicine News:Health News:New potential treatment for muscular dystrophy appears to be safe 2Health News:Medco Breaks Ground For World's Largest Automated Pharmacy 2Health News:Medco Breaks Ground For World's Largest Automated Pharmacy 3Health News:Medco Breaks Ground For World's Largest Automated Pharmacy 4Health News:Medco Breaks Ground For World's Largest Automated Pharmacy 5Health News:Hospital Leaders Urge Legislators Not to Further Destabilize Florida's Healthcare Landscape 2Health News:Hospital Leaders Urge Legislators Not to Further Destabilize Florida's Healthcare Landscape 3Health News:Late Use of Aromatase Inhibitor Still Effective Against Breast Cancer 2Health News:Late Use of Aromatase Inhibitor Still Effective Against Breast Cancer 3
All Day Comfort for the Lower Body...
All Day Comfort for the Lower Body...
All Day Comfort for the Upper Body...
The Skirts and Vests are made with .50mm Pb in the front and .25mm Pb in the back. When worn, the overlap areas in the front of both the skirt and vest provide 1.0mm Pb protection. The velcro fastene...
Medicine Products: